ATE278792T1 - Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten - Google Patents

Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten

Info

Publication number
ATE278792T1
ATE278792T1 AT00201738T AT00201738T ATE278792T1 AT E278792 T1 ATE278792 T1 AT E278792T1 AT 00201738 T AT00201738 T AT 00201738T AT 00201738 T AT00201738 T AT 00201738T AT E278792 T1 ATE278792 T1 AT E278792T1
Authority
AT
Austria
Prior art keywords
adenovirus
serotypes
tropism
proteins
gene transfer
Prior art date
Application number
AT00201738T
Other languages
English (en)
Inventor
Abraham Bout
Ronald Vogels
Menzo Jans Emco Havenga
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240209&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE278792(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Application granted granted Critical
Publication of ATE278792T1 publication Critical patent/ATE278792T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00201738T 1999-05-17 2000-05-16 Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten ATE278792T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99201545 1999-05-17

Publications (1)

Publication Number Publication Date
ATE278792T1 true ATE278792T1 (de) 2004-10-15

Family

ID=8240209

Family Applications (6)

Application Number Title Priority Date Filing Date
AT07106044T ATE485382T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus des ad26-serotyps
AT05077719T ATE445018T1 (de) 1999-05-17 2000-05-16 Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
AT07106036T ATE519855T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus des serotyps ad11
AT04077434T ATE364707T1 (de) 1999-05-17 2000-05-16 Rekombinanter humaner adenovirus-serotyp 35
AT00201738T ATE278792T1 (de) 1999-05-17 2000-05-16 Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
AT07106054T ATE519854T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus auf basis von serotyp 48 (ad48).

Family Applications Before (4)

Application Number Title Priority Date Filing Date
AT07106044T ATE485382T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus des ad26-serotyps
AT05077719T ATE445018T1 (de) 1999-05-17 2000-05-16 Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
AT07106036T ATE519855T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus des serotyps ad11
AT04077434T ATE364707T1 (de) 1999-05-17 2000-05-16 Rekombinanter humaner adenovirus-serotyp 35

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07106054T ATE519854T1 (de) 1999-05-17 2000-05-16 Rekombinantes adenovirus auf basis von serotyp 48 (ad48).

Country Status (14)

Country Link
EP (6) EP1550722B1 (de)
JP (2) JP4843145B2 (de)
KR (1) KR100741247B1 (de)
AT (6) ATE485382T1 (de)
AU (1) AU777041B2 (de)
CA (1) CA2372655C (de)
CY (4) CY1106762T1 (de)
DE (4) DE60035229T2 (de)
DK (6) DK1816205T3 (de)
ES (5) ES2231103T5 (de)
IL (3) IL146479A0 (de)
NZ (1) NZ515582A (de)
PT (5) PT1816204E (de)
WO (1) WO2000070071A1 (de)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1191105A1 (de) * 2000-09-25 2002-03-27 Galapagos Genomics B.V. Gentransfervektoren mit einer Gewebsspezifität für T-Lymphozyten
AU6368901A (en) 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US20040033605A1 (en) * 2000-09-20 2004-02-19 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
EP1195440A1 (de) * 2000-10-06 2002-04-10 Introgene B.V. Genverabreichung-Vektoren für Stammzellen
WO2002029073A2 (en) * 2000-10-06 2002-04-11 Crucell Holland B.V. Gene delivery vectors for stem cells
ATE449859T1 (de) 2001-01-04 2009-12-15 Goeran Wadell Virusvektor zur gentherapie
EP1377672A2 (de) 2001-02-23 2004-01-07 Novartis AG Vektorkonstrukte
AU2003210661A1 (en) * 2002-01-24 2003-09-02 Novartis Ag Fiber shaft modifications for efficient targeting
PT1497438E (pt) * 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
CA2478508C (en) * 2002-04-25 2013-07-02 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
JP4237449B2 (ja) * 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP2258850B1 (de) 2002-12-17 2013-07-17 Crucell Holland B.V. Rekombinanter virus-basierter malaria impfstoff
JP2007530004A (ja) * 2003-07-18 2007-11-01 オニックス ファーマシューティカルズ，インコーポレイティド 疾患を処置するためのサブグループｂアデノウイルスベクター
AU2005214090B2 (en) 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
EP1737885A2 (de) * 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Verwendung von adenoviralen vektoren zur erzeugung einer immunantwort
ATE491799T1 (de) 2004-05-26 2011-01-15 Bayer Schering Pharma Ag Chimäre adenoviren zur verwendung in der krebsbehandlung
KR101253363B1 (ko) 2004-10-13 2013-04-15 베쓰 이스라엘 디코니스 메디칼 센터 인크 개선된 아데노바이러스 벡터 및 그것의 용도
NZ555907A (en) 2004-11-16 2009-12-24 Aeras Global Tb Vaccine Found Multivalent vaccines comprising recombinant viral vectors
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
CA2616221C (en) 2005-07-22 2011-07-05 Crucell Holland B.V. Cell line for producing coronaviruses
WO2007104792A2 (en) * 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
EP2461826A2 (de) 2009-08-07 2012-06-13 Transgene SA Zusammensetzung zur behandlung von hbv-infektionen
KR101820980B1 (ko) 2010-02-15 2018-01-22 얀센 백신스 앤드 프리벤션 비.브이. Ａｄ 26 아데노바이러스 벡터를 제조하는 방법
US20120315696A1 (en) * 2010-02-15 2012-12-13 Alfred Luitjens METHOD FOR THE PRODUCTION OF Ad26 ADENOVIRAL VECTORS
AP3390A (en) 2010-09-20 2015-08-31 Crucell Holland Bv Therapeutic vaccination against active tuberculosis
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CN102260712B (zh) * 2011-05-31 2013-10-02 北京锤特生物科技有限公司 溶肿瘤能力增强的B型人腺病毒Ad11突变体的构建和应用
PL2825640T3 (pl) 2012-03-12 2016-10-31 Partie rekombinowanych adenowirusów o zmienionych końcach
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
AP2014007994A0 (en) 2012-03-22 2014-10-31 Crucell Holland Bv Vaccine against rsv
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
EP2855685B1 (de) 2012-05-24 2017-03-08 Janssen Vaccines & Prevention B.V. Adenovirale vektoren zur transduktion von vaskulärem gewebe
KR20150058152A (ko) 2012-07-10 2015-05-28 트랜스진 에스아이 마이코박테리아 항원 백신
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
EP2920313B1 (de) 2012-11-16 2019-06-12 Beth Israel Deaconess Medical Center, Inc. Rekombinante adenoviren und verwendung davon
CA3115891A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
PE20151867A1 (es) 2013-04-25 2016-01-07 Crucell Holland Bv Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
JP6605480B2 (ja) 2014-01-09 2019-11-13 トランスジェン・ソシエテ・アノニム ヘテロオリゴマーマイコバクテリア抗原の融合物
HUE065565T2 (hu) 2014-09-03 2024-06-28 Bavarian Nordic As Módszerek és készítmények filovírus fertõzés elleni védõ immunitás elõidézésére
BR112017004202A2 (pt) 2014-09-03 2019-09-03 Bavarian Nordic As composições para intensificar respostas imunes e seus usos
DK3198009T3 (da) 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
EA037583B1 (ru) 2014-09-26 2021-04-16 Бет Изрейэл Диконисс Медикал Сентер, Инк. Способы и композиции для индукции защитного иммунитета против инфекции вирусом иммунодефицита человека
EP3421046A1 (de) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutische hpv16-impfstoffe
US10570417B2 (en) 2015-04-14 2020-02-25 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
JP6931229B2 (ja) 2015-04-30 2021-09-01 サイオクサス セラピューティクス リミテッド Ｂ７タンパク質をコードする腫瘍溶解性アデノウイルス
CA2991002C (en) 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
CN107847581B (zh) 2015-07-07 2022-03-22 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EA037295B1 (ru) 2015-08-20 2021-03-05 Янссен Вэксинс Энд Превеншн Б.В. Терапевтические вакцины против hpv18
EA038974B1 (ru) 2015-12-15 2021-11-17 Янссен Вэксинс Энд Превеншн Б.В. Антигены вируса иммунодефицита человека, векторы, композиции и способы их применения
DK3389682T3 (da) 2015-12-17 2022-01-24 Psioxus Therapeutics Ltd Gruppe b-adenovirus, der koder for et anti-tcr-kompleks-antistof eller -fragment
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
EP3390645B1 (de) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogene genexpression eines therapeutischen adenovirus mit geringem einfluss auf die virale kinetik
MY193584A (en) 2016-04-05 2022-10-19 Janssen Vaccines & Prevention Bv Vaccine against rsv
PT3439672T (pt) 2016-04-05 2021-02-24 Janssen Vaccines & Prevention Bv Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
BR112018072372A2 (pt) 2016-05-02 2019-02-19 Janssen Vaccines & Prevention B.V. combinações de vacina terapêutica contra o hpv
US10953087B2 (en) 2016-05-30 2021-03-23 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion RSV F proteins
MA45381A (fr) 2016-06-16 2021-04-21 Janssen Vaccines & Prevention Bv Formulation de vaccin contre le vih
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018011196A1 (en) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Hpv vaccines
US10925955B2 (en) 2016-07-15 2021-02-23 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against a Marburg virus infection
WO2018011768A1 (en) 2016-07-15 2018-01-18 Janssen Vaccines And Prevention B.V. Methods and compositions for inducing protective immunity against a marburg virus infection
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
WO2018041827A1 (en) 2016-08-29 2018-03-08 Psioxus Therapeutics Limited Adenovirus armed with bispecific t cell engager (bite)
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CA3053212C (en) 2017-02-09 2021-04-13 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
EP3606553A1 (de) 2017-04-06 2020-02-12 Janssen Vaccines & Prevention B.V. Mva-bn- und ad26.zebov- oder ad26.filo-prime-boost-schema
US11229692B2 (en) 2017-05-17 2022-01-25 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
WO2018210871A1 (en) 2017-05-17 2018-11-22 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against rsv infection
US11229693B2 (en) 2017-06-15 2022-01-25 Janssen Vaccines & Prevention B.V. Poxvirus vectors encoding HIV antigens, and methods of use thereof
CN111163800A (zh) 2017-09-15 2020-05-15 扬森疫苗与预防公司 用于安全诱导针对rsv的免疫的方法
WO2019099970A1 (en) 2017-11-20 2019-05-23 Janssen Pharmaceuticals Inc. Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
EP3723771A4 (de) 2017-12-11 2022-04-06 Beth Israel Deaconess Medical Center, Inc. Rekombinante adenoviren und verwendungen davon
BR112020012273A2 (pt) 2017-12-19 2020-11-24 Janssen Sciences Ireland Unlimited Company métodos e composições para induzir uma resposta imune contra o vírus da hepatite b (hbv)
CA3096099A1 (en) 2018-04-09 2019-10-17 Salk Institute For Biological Studies Oncolytic adenovirus compositions with enhanced replication properties
US11713469B2 (en) 2018-07-20 2023-08-01 Janssen Vaccines & Prevention B.V. Recombinant adenoviral vector expressing Zika antigen with improved productivity
EP3880243A1 (de) 2018-11-13 2021-09-22 Janssen Vaccines & Prevention B.V. Stabilisierte präfusionierte rsv-f-proteine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US20220273787A1 (en) 2019-05-15 2022-09-01 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine
US20220193219A1 (en) 2019-05-15 2022-06-23 Janssen Vaccines & Prevention B.V. Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
CN111337042B (zh) * 2020-03-13 2021-11-02 湖北大学 一种车辆路径规划方法及系统
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN116367854A (zh) 2020-07-08 2023-06-30 杨森科学爱尔兰无限公司 针对hbv的rna复制子疫苗
GB202013940D0 (en) 2020-09-04 2020-10-21 Synpromics Ltd Regulatory nucleic acid sequences
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
WO2022140759A2 (en) 2020-12-23 2022-06-30 Janssen Biotech, Inc. Neoantigen peptide mimics
WO2023198815A1 (en) 2022-04-14 2023-10-19 Janssen Vaccines & Prevention B.V. Sequential administration of adenoviruses
CN121712889A (zh) * 2023-08-28 2026-03-20 国立大学法人大阪大学 重组溶瘤腺病毒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
IL160406A0 (en) 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
JP4683727B2 (ja) * 1999-03-04 2011-05-18 クルーセル ホランド ベスローテン フェンノートシャップ 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
EP2297187A1 (de) * 2008-06-03 2011-03-23 Okairos AG Impfstoff zur prävention und therapie von hcv-infektionen

Also Published As

Publication number Publication date
CY1112008T1 (el) 2015-11-04
EP1681353A1 (de) 2006-07-19
EP1818408B1 (de) 2011-08-10
DE60045138D1 (de) 2010-12-02
PT1550722E (pt) 2007-09-25
IL214413A0 (en) 2011-09-27
DE60043126D1 (de) 2009-11-19
DK1054064T4 (da) 2010-05-03
DE60014489T3 (de) 2010-08-12
ATE485382T1 (de) 2010-11-15
CY1112189T1 (el) 2015-12-09
PT1818408E (pt) 2011-11-15
KR20020028879A (ko) 2002-04-17
JP2011224014A (ja) 2011-11-10
WO2000070071A1 (en) 2000-11-23
DK1818408T3 (da) 2011-10-17
DK1681353T3 (da) 2010-01-04
DK1816205T3 (da) 2011-11-21
NZ515582A (en) 2003-11-28
PT1816205E (pt) 2011-11-15
EP1816205A1 (de) 2007-08-08
PT1054064E (pt) 2005-02-28
ATE445018T1 (de) 2009-10-15
EP1054064B2 (de) 2009-12-16
CA2372655C (en) 2011-11-15
ES2231103T5 (es) 2010-04-15
EP1816204A1 (de) 2007-08-08
IL146479A0 (en) 2002-07-25
EP1816205B1 (de) 2011-08-10
IL214413A (en) 2014-04-30
ES2231103T3 (es) 2005-05-16
AU777041B2 (en) 2004-09-30
PT1816204E (pt) 2011-01-24
EP1681353B1 (de) 2009-10-07
ATE519855T1 (de) 2011-08-15
EP1818408A1 (de) 2007-08-15
DK1816204T3 (da) 2011-01-24
KR100741247B1 (ko) 2007-07-19
AU4954700A (en) 2000-12-05
ES2372824T3 (es) 2012-01-26
ES2289426T3 (es) 2008-02-01
EP1054064A1 (de) 2000-11-22
CY1111494T1 (el) 2015-08-05
EP1550722B1 (de) 2007-06-13
DK1054064T3 (da) 2005-01-10
DK1550722T3 (da) 2007-10-08
EP1816204B1 (de) 2010-10-20
ATE364707T1 (de) 2007-07-15
IL146479A (en) 2011-12-29
ES2372823T3 (es) 2012-01-26
DE60014489T2 (de) 2005-11-24
CA2372655A1 (en) 2000-11-23
ATE519854T1 (de) 2011-08-15
JP5335037B2 (ja) 2013-11-06
DE60035229D1 (de) 2007-07-26
EP1550722A1 (de) 2005-07-06
DE60014489D1 (de) 2004-11-11
DE60035229T2 (de) 2008-02-21
JP2002543846A (ja) 2002-12-24
ES2354578T3 (es) 2011-03-16
CY1106762T1 (el) 2012-05-23
EP1054064B1 (de) 2004-10-06
JP4843145B2 (ja) 2011-12-21

Similar Documents

Publication Publication Date Title
ATE278792T1 (de) Von adenovirus abgeleitete gentransfervehikel, die zumindest ein element des adenovirus typ 35 enthalten
EP1522588A3 (de) Hilfsfunktionen für die rekombinante AAV-Virionherstellung
TW428026B (en) Bifunctional protein, preparation and use
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
WO2003099859A3 (de) Neue verwendung von adenoviren und dafür codierenden nukleinsäuren
EP1057654A3 (de) Verfahren zum Binden von Blättern mit Hilfe von Bildaufzeichnungsmaterial
DE50208824D1 (de) Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
AU2002228805A1 (en) Antisense modulation of damage-specific dna binding protein 2, p48 expression
ZA200006309B (en) A polypeptide comprising the amino acid of an n-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof.
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO1992011367A3 (en) Lipid receptors for microorganisms and corresponding adhesins, dna sequences encoding adhesins, and use thereof
ATE428793T1 (de) Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
Takao et al. Derivatives of sperm-activating peptide III (SAP-III) associated with eggs of sand dollars, Clypeasterjaponicus and Astriclypeusmanni
Aanpreung et al. The upper endoscopy in upper gastrointestinal hemorrhage of children.
Raibekas et al. Isolation and comparative studies of two fluorescent flavoproteins of luminous bacteria Photobacterium leiognathi.
Powers Raising Caen.
Chin Rescuing Glycine
Asgharian et al. A comparative monomolecular film study of 1, 2-di-O-palmitoyl-3-O-(. alpha.-and. beta.-D-glucopyranosyl)-sn-glycerols [Erratum to document cited in CA111 (11): 92542q]
Moon With This, it's 40 Volumes
Nishida From Cell Motility to Cell Biology
Banks The upper airway.
Catalan Hinsehen ist besser,«Skolast», a. XXXVIII, n. 3/4, 1994
AU2002226892A1 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
ES1039985U (es) Un juego.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1054064

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1054064

Country of ref document: EP